Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections (ToPICL)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to determine if the overall central venous catheter related infection rate can be reduced by the application of Polysporin Triple Therapy ointment to the insertion site.
| Condition | Intervention |
|---|---|
|
Blood Stream Infections Skin Diseases, Infectious |
Drug: Polysporin Triple Therapy ointment Other: Petroleum Jelly |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Pilot Study: Topical Antibiotics for Prevention of ICU Central Line Infections |
- Overall number of line related infections (local and blood borne) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Length of ICU stay [ Time Frame: 7 months ] [ Designated as safety issue: No ]
- Length of hospital stay [ Time Frame: 7 months ] [ Designated as safety issue: No ]
- Prevalence of methicillin-resistant Staphylococcus Aureus (MRSA) [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 140 |
| Study Start Date: | November 2009 |
| Study Completion Date: | January 2011 |
| Primary Completion Date: | January 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Polysporin Triple Therapy
Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
|
Drug: Polysporin Triple Therapy ointment
Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
Other Name: Polysporin Triple Therapy (gramicidin, polymixin, bacitracin)
|
|
Placebo Comparator: Placebo
Petroleum jelly
|
Other: Petroleum Jelly
Petroleum jelly applied to the insertion point at the time of CVC placement and twice within the first week.
Other Name: Vaseline
|
Detailed Description:
Previous studies in the dialysis population have found a reduction in local and system central venous catheter related infections with the application of topical antibiotics to the insertion point. One such study found a mortality benefit with Polysporin Triple Therapy ointment. We intend to determine if this preparation can reduce overall line infection rates in the ICU environment through its application at the time of line insertion and twice more the following week.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- all patients admitted to the ICU requiring a central venous catheter
Exclusion Criteria:
- previous line infection during same ICU stay
- CVC for hemodialysis
Contacts and Locations| Canada, British Columbia | |
| Royal Columbian Hospital | |
| New Westminster, British Columbia, Canada, V3L 1A1 | |
| Principal Investigator: | Steven Reynolds, MD | Fraser Health Authority |
More Information
Additional Information:
Publications:
| Responsible Party: | Dr. Steven Reynolds, Fraser Health |
| ClinicalTrials.gov Identifier: | NCT00990392 History of Changes |
| Other Study ID Numbers: | Kerrie-333333 |
| Study First Received: | October 5, 2009 |
| Last Updated: | June 22, 2011 |
| Health Authority: | Canada: Ethics Review Committee |
Keywords provided by Fraser Health:
|
Blood stream infections Catheter related infections Central venous catheter related infections Line sepsis Topical antibiotics |
Bacitracin Polymixin Gramicidin Polysporin Triple Therapy Intensive care unit |
Additional relevant MeSH terms:
|
Communicable Diseases Infection Skin Diseases Skin Diseases, Infectious Anti-Bacterial Agents Bacitracin Gramicidin Polymyxins |
Polymyxin B Petrolatum Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Anti-Infective Agents, Local Emollients Dermatologic Agents |
ClinicalTrials.gov processed this record on May 19, 2013